Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer

Oncology Reports

Volumn 5, Issue 3, 1998, Pages 649-652

  De Vita, Ferdinando ^a   Orditura, Michele ^a   Auriemma, Annunziata ^a   Infusino, Stefania ^a   Roscigno, Annarita ^a   Catalano, Giuseppe ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Cisplatin; IL 6; Non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0031969898     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.5.3.649     Document Type: Article

References (34)

1. Grilli R, Oxman AD and Julian JA: Chemotherapy for advanced non small cell lung cancer: how much benefit is enough? J Clin Oncol 11: 1866-1872, 1993.
2. Kishimoto T: The biology of interleukin-6. Blood 74: 1-10, 1989.
3. Miles ASA, Rezai AR, Salazau-Gonzalez JF, Meyden MT, Stevens RH and Logan DM: AIDS Kaposi sarcoma-derived cells produce and respond to interleukin-6. Proc Natl Acad Sci USA 87: 4068-4072, 1990.
4. Zhang XG, Klein B and Bataille R: Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74: 11-13, 1989.
5. Miki S, Iwano M, Miki Y, Yamamoto M, Tang B, Yokokawa K, Sonoda T, Hirano T and Kishimoto T: Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 250: 607-610, 1989.
6. Bataille R, Jourdan M, Zhang XG and Klein B: Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 84: 2008-2011, 1989.
7. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Touraut JM, Moskovtchenko JF, Philip T and Favrot M: Serum levels of interleukin-6 as a prognostic factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
8. Strassmann G, Fong M, Kenney JS and Jacob CO: Evidence for the involvement of interleukin-6 in experimental cancer cachexia. J Clin Invest 89: 1681-1684, 1992.
9. Katsumata N, Eguchi K, Andou M, Fukuda M, Jamamoto N, Shiraishi J, Nomura N, Oshita F, Tamura T, Shinkai T and Saijo N: Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res 2: 553-559, 1996.
10. Hermanek P and Sobin LH (eds): International Union Against Cancer: TNM Classification of Malignant Tumors. Springer Verlag, New York, pp121-144, 1987.
11. Armitage P and Berry G (eds): Statistical Methods in Medical Reseach. Blackwell Scientific, Oxford, pp200-205, 1987.
12. Yanagawa H, Sone S, Takahashi Y, Haku T, Yano S, Shinohara T and Ogura T: Serum levels of interleukin-6 in patients with lung cancer. Br J Cancer 71: 1095-1098, 1995.
13. Erroi A, Sirom M, Chiaffarino F, Guo CZ, Mengozzi M and Mantovani A: IL-1 and IL-6 release by tumor- associated macrophages from human ovarian carcinoma. Int J Cancer 44: 795-801, 1989.
14. Watson JM, Sensintaffar JL, Berek JS and Maza OM: Constitutive production of interleukin-6 by ovarian cancer cell lines and by primary ovarian cultures. Cancer Res 50: 6959-6965, 1990.
15. Tabidzadeh SS, Poubouris D, May LT and Sehgal PB: Interleukin-6 immunoreactivity in human tumors. Am J Pathol 135: 427-433, 1989.
16. Tanekawa J, Kaneko J, Fukumoto M, Fukatsu A, Hirano T, Fukuyama H, Nakayama H, Fujita J and Yoshida O: Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Inst 83: 1668-1672, 1991.
17. Yangawa H, Sone S, Munekata M, Atagi S, Nii A and Ogura T: IL-6 in malignant pleural effusion and its augmentation by intra-pleural instillation of IL-2. Clin Exp Immunol 88: 207-212, 1992.
18. Mizuno K, Sone S, Orino E, Nii A and Ogura T: Autonomous expression of cytokine genes by human lung cancer cells and their paracrine regulation. Jpn J Cancer Res 85: 179-186, 1994.
19. Reibnegger G, Krainer M, Herold M, Ludwig H, Wachter H, and Huber H: Predictive value of interleukin-6 and neopterin in patients with multiple myeloma. Cancer Res 52: 179-186, 1992.
20. Plante M, Rubin S, Wong GY, Federici M, Fiustad C and Gastl GA: Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 73: 1882-1888, 1994.
21. Van Meir E, Sawamura Y, Diserens AC, Hamow MF and De Tribolet N: Human glioblastoma cells release interleukin-6 in vivo and in vitro. Cancer Res 50: 6683-6688, 1990.
22. Tamm I, Kikuchi T, Cardinale J and Krnegher J: Cell-adhesion-disrupting action of interleukin-6 in human ductal breast carcinomas cells. Proc Natl Acad Sci USA 91: 3329-3333, 1994.
23. Luger TA, Krutmann J, Kirnbauer R, Urbanski A, Schwartz T, Klappacher G, Kock A, Micksche M, Malejczyk J, Schauer E, May LT and Sehgal PB: IFN-β2/IL-6 augments the activity of human natural killer cells. J Immunol 143: 1206-1209, 1989.
24. Tanner J and Tosato G: Impairment of natural killer functions by interleukin-6 increases lymphoblastoid cell tumorigenicity in athymic mice. J Clin Invest 88: 239-247, 1991.
25. Zhou D, Munster A and Wincherch RA: Pathologic concentrations of interleukin-6 inhibit T cell responses via induction of activation of TGF-β. FASEB J 5: 2582-2585, 1991.
26. Moy MP, Holmes EC and Golub SM: Depression of NK cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 45: 57-60, 1985.
27. Siziopikou KP, Harris JE, Casey L, Nawas Y and Braun DP: Impaired tumoricidal function of alveolar macrophages from patients with non small cell lung cancer. Cancer 68: 1035-1044, 1991.
28. Uchida A, Kariya Y, Okamoto N, Sugie K, Fujimoto T and Yagita M: Prediction of postoperative clinical course by autologous tumor killing activity in lung cancer patients. J Natl Cancer Inst 82: 1697-1701, 1990.
29. Dunlap NE, Lane VG, Cloud G and Tilden A: In vitro NK and LAK activity in patients with bronchosenic carcinoma. Cancer 66: 1499-1504, 1990.
30. Pisani RJ, Krco CJ, Wold LE and Mckean DJ: Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non small cell lung cancer. Am J Clin Pathol 92: 435-446, 1989.
31. Inge TH, Hoover SK, Susskind BM, Banet SK and Bear HD: Inhibition of tumor-specific cytotoxic T lymphocyte responses by trasforming growth factor β1. Cancer Res 52: 1386-1392, 1992.
32. Scambia G, Testa U, Benedetti Panici P, Martucci R, Foti E, Petrini M, Amoroso M, Masciullo V, Peschle C and Mancuso S: Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer 97: 318-323, 1994.
33. Johnson MT, Gotlieb H, Rabbi M, Martinez-Maza O and Berek JS: Induction of cisplatin resistance and metallothionein expression by interleukin-6. Gynecol Oncol 49: 110-113, 1993.
34. Borsellino N, Belldegrun A and Bonavida B: Endogenous interleukin-6 is a resistance factor for cis-Diamminechloro-platinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55: 4633-4639, 1995.